In the menopausal period, the reduction in the estradiol level is frequently accompanied by symptoms such as vasomotor symptoms, sleep disorders, mood changes and urogenital atrophy. Hormone therapy is commonly used to prevent these symptoms in this period. Tibolone has a positive effect on bone, vagina, climacteric symptoms, mood state, sexual well-being without any induction to the endometrium and breast in the postmenopausal women. In our research we studied the tolerability of the drugs, the ratio of vaginal bleeding and breast symptoms in the patients who use tibolone for climacteric symptoms.
Materials and Methods :After the tibolone treatment (2,5 mg/day); the women are evaluated in three periods [first month (1. cycle), third month (2. and 3. cycle) and sixth month(5. and 6. cycle)]. All of 88 postmenopausal women (50 natural menopause -38 surgical menopauses) breast symptoms are determined and in 50 women with natural menapause symptom of vaginal bleeding are determined.
Results: 20% of women (10/50) vaginal bleeding/spotting symptoms are occurred. In 13% of women breast tenderness is determined. For three periods' average VAS scores are determined respectively; 2.5, 2.3 and 2.5.
Conclusion: Our results showed that treatment with tibolone is related with high concordance and low vaginal bleeding and breast symptoms.